{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Austria Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/at/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/at/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from Austria, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:55c67ba2272dea5cc0cd1ede8ac29dbc25eda74abf99d734107491a87e3cb10b", "url": "https://finance.yahoo.com/markets/stocks/articles/bmrn-vs-ilmn-stock-better-154005188.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bmrn-vs-ilmn-stock-better-154005188.html", "title": "BMRN vs. ILMN: Which Stock Is the Better Value Option?", "content_text": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits", "date_published": "2026-08-12T15:40:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/945d0ea3-d09a-46cb-8f81-236fdbe38091/"}]}}, {"id": "source:382c5f901b3fe24d52e18b823bbce0bd9ccc848d9b2a6c3a8e46d6d6e92c6cd4", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-stock-know-152522069.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-stock-know-152522069.html", "title": "BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know", "content_text": "BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the morning session after an analyst at Canaccord Genuity raised the company's price target to $114 from $111 and maintained a \"Buy\" rating. The positive revision followed BioMarin's strong second-quarter 2026 earnings report. The company's revenue growth was driven by the addition of products from the recently closed Amicus acquisition. Following the strong results, BioMarin raised its fiscal 2026 guidance for total revenue, Voxzogo re", "date_published": "2026-08-12T15:25:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/945d0ea3-d09a-46cb-8f81-236fdbe38091/"}]}}, {"id": "source:effa4ed1caf33496b3380870fdaa9fab5b585d707cfd898d9224cf86f7ba93bf", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-targets-faster-deleveraging-amicus-140505463.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-targets-faster-deleveraging-amicus-140505463.html", "title": "BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth", "content_text": "Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. BioMarin raised its financial outlook after second-quarter revenue approached $1 billion, lifting 2025 revenue guidance to $3.875 billion\u2013$3.925 billion and non-GAAP EPS guidance to $4.90\u2013$5.10. The Amicus acquisition added Galafold and the Pombiliti/Opfolda Pompe franchise, with significant geographic expansion and diagnosis opportunities. BioMarin now expects to reduce leverage below 2.5 times by mid-next year, about a year ahead of its original target, while preserving Amicus' commercial capabilities", "date_published": "2026-08-12T14:05:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/945d0ea3-d09a-46cb-8f81-236fdbe38091/"}]}}, {"id": "source:307c68c8377bcf013ad783581ce907b734df56f45e0558685346ed0bf0510ade", "url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "external_url": "https://finance.yahoo.com/healthcare/articles/regn-soars-21-9-month-143000494.html", "title": "REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?", "content_text": "The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investmen", "date_published": "2026-08-11T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "REGN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/769c4489-fb46-4579-964a-3d2425edf2bd/"}]}}, {"id": "source:64de25c2f0b03d23ec231b6756b869046803bacae8333fa1a1145a28592467d9", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "title": "argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the sa", "date_published": "2026-08-11T11:11:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ARGX"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARGX", "name": "argenx SE", "sentiment_url": "https://sharemaestro.com/sentiment/f2cafc85-73f2-4445-a9ba-c78c7863bcca/"}]}}, {"id": "source:fafc61c50e634d6c45aecdb1952334394a1495194e5acc1d0607da1b1f8882e8", "url": "https://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-arbutus-biopharma-corporation-abus-001821145.html", "title": "Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?", "content_text": "A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with a massive, non-dilutive liquidity boost while removing a significant overhang for Moderna as it seeks to expand its commercial pipeline beyond COVID-19.Could Arbutus Biopharma Corporation (ABUS) Turn Its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech", "date_published": "2026-08-11T00:18:21+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MRNA"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRNA", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9ece5cf3-2cd2-415f-8de3-e946a8e42ed0/"}]}}, {"id": "source:adf2973fc0df2ccccaa28dfdfb19ac492d2f2868c4a5caabc91d668978a6a132", "url": "https://finance.yahoo.com/healthcare/articles/lakefront-biotherapeutics-reports-half-2026-200100211.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lakefront-biotherapeutics-reports-half-2026-200100211.html", "title": "Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update", "content_text": "Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least \u20ac1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~\u20ac2B, and now includes \u20ac50M share repurchase Mechelen, Belgium; August 10, 2026, 22.01 CET; regulated information \u2013 Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced its half-year 2026 financial results and provided a second quarter and post-period business upda", "date_published": "2026-08-10T20:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "LKFT"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LKFT", "name": "Lakefront Biotherapeutics NV", "sentiment_url": "https://sharemaestro.com/sentiment/de4a94e6-2fef-4859-83a1-4f937f3f2e93/"}]}}, {"id": "source:74366017fd2c0623307ac79147d5e34c80cb65bb87cd977037a35a42aa00bf8f", "url": "https://finance.yahoo.com/healthcare/articles/biomarin-participate-canaccord-genuity-46th-130500741.html", "external_url": "https://finance.yahoo.com/healthcare/articles/biomarin-participate-canaccord-genuity-46th-130500741.html", "title": "BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston", "content_text": "SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. About BioMarin BioMarin is a leading, global rare disease biotechnolo", "date_published": "2026-08-10T13:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "BioMarin Pharmaceutical Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/945d0ea3-d09a-46cb-8f81-236fdbe38091/"}]}}, {"id": "source:d68b0a1d48719cb431f473b25ba4d707fa326d03aa64ef0c19ecde50c7fe852e", "url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/09/3341497/9788/en/bronstein-gewirtz-grossman-llc-urges-regeneron-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html", "title": "Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm", "content_text": "NEW YORK, Aug. 09, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the \u201cClass Period\u201d). Such investors are encouraged to join this", "date_published": "2026-08-09T16:00:00+00:00", "authors": [{"name": "globenewswire.com"}], "tags": ["Regulatory and legal", "REGN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/769c4489-fb46-4579-964a-3d2425edf2bd/"}]}}, {"id": "source:2668ba56fc8490dfdf15ee7d2ca8fb74a8b9a2a4ea525fbefdc9b370d1a7b91c", "url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/regeneron-pharmaceuticals-regn-keeps-buybacks-231155132.html", "title": "Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals' recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests ", "date_published": "2026-08-08T23:11:55+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "REGN"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/769c4489-fb46-4579-964a-3d2425edf2bd/"}]}}, {"id": "source:8c2967a817d4b5440004ff317104d2ca6f0b04853c79555e2b24b110d05f58c0", "url": "https://www.nasdaq.com/articles/moderna-mrna-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/moderna-mrna-q2-2026-earnings-call-transcript", "title": "Moderna (MRNA) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth driven by international strategic partnerships and stand-ready manufacturing revenue.Net Loss -- $782 million, an improvement of 5% compared to the prior year.Loss Per Share -- $1.97, improving from a loss of $2.13 in the second quarter of 2025.Cash and Investments -- $6.9 billion, a decrease from $7.5", "date_published": "2026-08-08T02:32:56+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "MRNA"], "_sharemaestro": {"country": "Austria", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MRNA", "name": "Moderna, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/9ece5cf3-2cd2-415f-8de3-e946a8e42ed0/"}]}}]}